Jiayin Biomedical Technology Completed $1.4 Million of Pre Series A Financing

On May 22, 2019, Jiayin Biomedical Technology has announced the completion of 1.4 million dollars of pre-Series A. This round of financing was backed by Xiangxiang Capital. The funds will be used to accelerate the clinical product development with genetics technology.

Since its establishment in 2014, Jiayin Biomedical Technology has been committed to the development of epigenetic technology. Right now, Jiayin Biomedical Technology has become one of the leaders in the field of epigenetic in China. The company’s core products cover the fields of ChIP-seq, ATAC-seq, MeRIP-seq/acRIP-seq.

Epigenetic technology can be applied to many fields such as early tumor screening, tumor guiding medication, genetic disease diagnosis and drug development. In the field of oncology, Jiayin Biomedical Technology has developed a complete set of early cancer screening markers that directly target micro cfDNA after years of research and development. At this moment, these related products have entered the stage of clinical trials.

About this round of financing, the CEO of Jiayin Biomedical Technology, said “ we are grateful for the support of Xiangxiang Capital for our team development. Jiayin Biomedical Technology welcomes teams in the field of epigenetics and clinical product development to create a better product for society”.

Founded in 2018, Xiangxiang Capital is a professional investment institution focusing on high-end manufacturing, information technology and biomedicine. The funds are mainly from the enterprises in Shenzhen, Dongguan, Guangzhou and Huizhou.